Journal of Cardiac Failure
Volume 16, Issue 9 , Pages 720-727 , September 2010

Acute Effects of Intravenous Nesiritide on Cardiac Contractility in Heart Failure

  • Sanjiv J. Shah, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
    • ,
  • Andrew D. Michaels, MD, MAS

      Affiliations

    • Division of Cardiology, Department of Medicine, University of Utah, Salt Lake City, UT
    • Corresponding Author InformationReprint requests: Andrew D. Michaels, MD, MAS, Division of Cardiology, University of Utah, 30 North 1900 East, Room 4A100, Salt Lake City, UT 84132-2401. Tel: (801) 585-1686; Fax: (801) 581-7735.

Received 6 September 2009 ,Revised 31 March 2010 ,Accepted 12 April 2010.

References 

  1. Shah SJ, Teerlink JR. Nesiritide: a reappraisal of efficacy and safety. Expert Opin Pharmacother. 2007;8:361–369
  2. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  3. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 2000;343:246–253
  4. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JaAMA. 2005;293:1900–1905
  5. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  6. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J. 2006;152:1084–1090
  7. Arora S, Clarke K, Srinivasan V, Gradman A. Effect of nesiritide on renal function in patients admitted for decompensated heart failure. QJM. 2007;100:699–706
  8. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007;116(11 Suppl):I134–I138
  9. Chow SL, Peng JT, Okamoto MP, Heywood JT. Effect of nesiritide infusion duration on renal function in acutely decompensated heart failure patients. Ann Pharmacother. 2007;41:556–561
  10. Iglesias JI, DePalma L, Hom D, Antoniotti M, Ayoub S, Levine JS. Predictors of mortality in adult patients with congestive heart failure receiving nesiritide—retrospective analysis showing a potential adverse interaction between nesiritide and acute renal dysfunction. Nephrol Dial Transplant. 2008;23:144–153
  11. Kurien S, Warfield KT, Wood CM, Miller WL. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide. Am J Cardiol. 2006;98:1627–1630
  12. Miller WL, Kurien S, Warfield KT, Wood CM, Jaffe AS. Lack of association between worsening renal function and mortality in heart failure patients treated with nesiritide. Int J Cardiol. 2008;126:234–239
  13. Owan TE, Chen HH, Frantz RP, et al. The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. J Card Fail. 2008;14:267–275
  14. Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50:1835–1840
  15. Zhang Q, Moalem J, Tse J, Scholz PM, Weiss HR. Effects of natriuretic peptides on ventricular myocyte contraction and role of cyclic GMP signaling. Eur J Pharmacol. 2005;510:209–215
  16. Kogler H, Schott P, Toischer K, et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression. Circulation. 2006;113:2724–2732
  17. Brusq JM, Mayoux E, Guigui L, Kirilovsky J. Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol. 1999;128:206–212
  18. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004;101:113–129
  19. Hirose M, Furukawa Y, Kurogouchi F, Nakajima K, Miyashita Y, Chiba S. C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J Pharmacol Exp Ther. 1998;286:70–76
  20. Mulumba M, Cemeus C, Dumont L, du Souich P, Ong H, Marleau S. Recombinant bovine growth hormone-induced reduction of atrial natriuretic peptide is associated with improved left ventricular contractility and reverse remodeling in cardiomyopathic UM-X7.1 hamsters with congestive heart failure. Growth Horm IGF Res. 2007;17:96–103
  21. Nir A, Zhang DF, Fixler R, Burnett JC, Eilam Y, Hasin Y. C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. Eur J Pharmacol. 2001;412:195–201
  22. Tajima M, Bartunek J, Weinberg EO, Ito N, Lorell BH. Atrial natriuretic peptide has different effects on contractility and intracellular pH in normal and hypertrophied myocytes from pressure-overloaded hearts. Circulation. 1998;98:2760–2764
  23. Lainchbury JG, Burnett JC, Meyer D, Redfield MM. Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. Am J Physiol Heart Circ Physiol. 2000;278:H33–H40
  24. Semigran MJ, Aroney CN, Herrmann HC, Dec GW, Boucher CA, Fifer MA. Effects of atrial natriuretic peptide on myocardial contractile and diastolic function in patients with heart failure. J Am Coll Cardiol. 1992;20:98–106
  25. Semigran MJ, Aroney CN, Herrmann HC, Dec GW, Boucher CA, Fifer MA. Effects of atrial natriuretic peptide on left ventricular function in hypertension. Hypertension. 1994;24:271–279
  26. Ohte N, Cheng CP, Suzuki M, Little WC. Effects of atrial natriuretic peptide on left ventricular performance in conscious dogs before and after pacing-induced heart failure. J Pharmacol Exp Ther. 1999;291:589–595
  27. Mizuno O, Onishi K, Dohi K, et al. Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure. Am J Cardiol. 2001;88:863–866
  28. Nakajima K, Onishi K, Dohi K, et al. Effects of human atrial natriuretic peptide on cardiac function and hemodynamics in patients with high plasma BNP levels. Int J Cardiol. 2005;104:332–337
  29. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441–1446
  30. Senzaki H, Chen CH, Kass DA. Single-beat estimation of end-systolic pressure-volume relation in humans. A new method with the potential for noninvasive application. Circulation. 1996;94:2497–2506
  31. Chen CH, Fetics B, Nevo E, et al. Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol. 2001;38:2028–2034
  32. Lee WS, Huang WP, Yu WC, Chiou KR, Ding PY, Chen CH. Estimation of preload recruitable stroke work relationship by a single-beat technique in humans. Am J Physiol Heart Circ Physiol. 2003;284:H744–H750
  33. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2005;18:1440–1463
  34. Hill JC, Palma RA. Doppler tissue imaging for the assessment of left ventricular diastolic function: a systematic approach for the sonographer. J Am Soc Echocardiogr. 2005;18:80–88quiz 89
  35. Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289:H501–H512
  36. Reichek N, Wilson J, St John Sutton M, Plappert TA, Goldberg S, Hirshfeld JW. Noninvasive determination of left ventricular end-systolic stress: validation of the method and initial application. Circulation. 1982;65:99–108
  37. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37:1221–1227

 See page 726 for disclosure information.

PII: S1071-9164(10)00198-3

doi: 10.1016/j.cardfail.2010.04.008

Journal of Cardiac Failure
Volume 16, Issue 9 , Pages 720-727 , September 2010

Article Tools

* Image Usage & Resolution